Low locoregional failure rates in selected breast cancer patients with tumor-positive sentinel lymph nodes who do not undergo completion axillary dissection

Cancer

Volumn 110, Issue 4, 2007, Pages 723-730

  Hwang, Rosa F ^a   Gonzalez Angulo, Ana M ^a   Yi, Min ^a   Buchholz, Thomas A ^a   Meric Bernstam, Funda ^a   Kuerer, Henry M ^a   Babiera, Gildy V ^a   Tereffe, Welela ^a   Liu, Diane D ^a   Hunt, Kelly K ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Breast cancer; Lymph node dissection; Radiotherapy; Sentinel lymph node biopsy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; FOLLOW UP; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SENTINEL LYMPH NODE BIOPSY; STATISTICAL ANALYSIS; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; AXILLA; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; COMBINED MODALITY THERAPY; DRUG THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MIDDLE AGED; PROGNOSIS; RADIOTHERAPY; SENTINEL LYMPH NODE BIOPSY;

EID: 34547863132     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22847     Document Type: Article

References (31)

1. Giuliano AE, Kirgan DM, Guenther M, et al. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994;220:391-401.
2. Krag D, Weaver D, Ashikaga T, et al. The sentinel node in breast cancer-a multicenter validation study. N Engl J Med. 1998;339:941-946.
3. Peintinger F, Reitsamer R, Stranzl H, et al. Comparison of quality of life and arm complaints after axillary lymph node dissection versus sentinel lymph node biopsy in breast cancer patients. Br J Cancer. 2003;89:648-652.
4. Blanchard D, Donohue J, Reynolds C, et al. Relapse and morbidity in patients undergoing sentinel lymph node biopsy alone or with axillary dissection for breast cancer. Arch Surg. 2003;138:482-487.
5. Purushotham A, Upponi S, Klevesath M, et al. Morbidity after sentinel lymph node biopsy in primary breast cancer: results from a randomized controlled trial. J Clin Oncol. 2005;23:4312-4321.
6. Giuliano AE, Dale P, Turner RR, et al. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg. 1995;222:394-399.
7. Leong S. Paradigm shift of staging and treatment for early breast cancer in the sentinel lymph node era. Breast J. 2006;12:S128-S133.
8. Singletary S, Allred C, Ashley P, et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol. 2002;20:3628-3636.
9. Greene FL, Page DL, Fleming ID, et al, eds. AJCC Cancer Staging Manual, 6th ed. New York, NY: Springer-Verlag; 2002.
10. Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005;23:7703-7720.
11. Grube BJ, Giuliano AE. Observation of the breast cancer patient with a tumor-positive sentinel node: implications of the ACOSOG Z0011 trial. Semin Surg Oncol. 2001;20:230-237.
12. Chu KU, Turner RR, Hansen NM, et al. Do all patients with sentinel node metastasis from breast carcinoma need complete axillary node dissection? Ann Surg. 1999;229:536-541.
13. Kamath BJ, Giuliano R, Dauway EL, et al. Characteristics of the sentinel lymph node in breast cancer predict further involvement of higher-echelon nodes in the axilla. Arch Surg. 2001;136:688-692.
14. Reynolds C, Mick R, Donohue JH, et al. Sentinel lymph node biopsy with metastasis: can axillary dissection be avoided in some patients with breast cancer? J Clin Oncol. 1999;17:1720-1726.
15. Turner RR, Chu KU, Qi K, et al. Pathologic features associated with nonsentinel lymph node metastases in patients with metastatic breast carcinoma in a sentinel lymph node. Cancer. 2000;89:574-581.
16. Hwang R, Krishnamurthy S, Hunt K, et al. Clinicopathologic factors predicting involvement of nonsentinel axillary nodes in women with breast cancer. Ann Surg Oncol. 2003;10:248-254.
17. Abdessalam SF, Zervos EE, Prasad M, et al. Predictors of positive axillary lymph nodes after sentinel lymph node biopsy in breast cancer. Am J Surg. 2001;182:316-320.
18. Weiser MR, Montgomery LL, Tan LK, et al. Lymphovascular invasion enhances the prediction of non-sentinel node metastases in breast cancer patients with positive sentinel nodes. Ann Surg Oncol. 2001;8:145-149.
19. Van Zee KJ, Manasseh D-ME, Bevilacqua JLB, et al. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol. 2003;10:1140-1151.
20. Lambert L, Ayers G, Hwang R, et al. Validation of a breast cancer nomogram for predicting nonsentinel lymph node metastases after a positive sentinel node biopsy. Ann Surg Oncol. 2006;13:310-320.
21. Soni NK, Carmalt HL, Gillett DJ, et al. Evaluation of a breast cancer nomogram for prediction of non-sentinel lymph node positivity. Eur J Surg Oncol. 2005;31:958-964.
22. Breslin TM, Cohen L, Sahin A, et al. Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer. J Clin Oncol. 2000;18:3480-3486.
23. Yared MA, Middleton LP, Smith TL, et al. Recommendations for sentinel lymph node processing in breast cancer. Am J Surg Pathol. 2002;26:377-382.
24. Fant JS, Grant MD, Knox SM, et al. Preliminary outcome analysis in patients with breast cancer and a positive sentinel lymph node who declined axillary dissection. Ann Surg Oncol. 2003;10:126-130.
25. Jeruss JS, Sener SF, Brinkmann EM, et al. Axillary recurrence after sentinel node biopsy. Ann Surg Oncol. 2005;12:34-40.
26. Naik AM, Fey JV, Gemignani M, et al. The risk of axillary relapse after sentinel lymph node biopsy for breast cancer is comparable with that of axillary lymph node dissection. Ann Surg. 2004;240:462-471.
27. Schlembach PJ, Buchholz TA, Ross MI, et al. Relationship of sentinel and axillary level I-II lymph nodes to tangential fields used in breast irradiation. Int J Radiat Oncol Biol Phys. 2001;51:671-678.
28. Pejavar S, Wilson LD, Haffty BG. Regional nodal recurrence in breast cancer patients treated with conservative surgery and radiation therapy (BCS+RT). Int J Radiat Oncol Biol Phys. 2006;66:1320-1327.
29. Gadd M, Harris J, Taghian A, et al. Prospective study of axillary radiation without axillary dissection for breast cancer patients with a positive sentinel node. Presented at the Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, December 8-11, 2005. Abstract 22.
30. European Organization for Research and Treatment of Cancer. Phase III randomized study of complete axillary lymph node dissection versus axillary radiotherapy in sentinel lymph node positive women with operable invasive breast cancer. Available at URL: http://www.clinicaltrials.gov/ct/show/NCT00014612. Accessed June 14, 2007.
31. Hurkmans CW, Borger JH, Rutgers EJT, et al. Quality assurance of axillary radiotherapy in the EORTC AMAROS trial 10981/22023: the dummy run. Radiother Oncol. 2003;68:233-240.